Core Lab Funding Program Grantees

The Core Lab Funding Program

This funding opportunity launched in Feb. 2019 and started accepting applications one month later. This program is an ongoing Biosciences Initiative funding opportunity that aims to enhance technology at existing core laboratories and/or create new core laboratories to advance the research capabilities of U-M investigators.

Research cores

Research cores are centralized facilities or labs that offer shared services, shared equipment, resources or expertise to scientific researchers. Cores are an important resource for students, staff and faculty, and can significantly impact research throughout the university.

Core Lab Funding Program grantees

Grantees of this program receive Biosciences Initiative support toward instruments that aid in understanding complex research challenges:

Mass Spectrometers

  • Biological Mass Spectrometry Facility
  • Principal investigator Brandon Ruotolo, professor of chemistry
  • Four mass spectrometers are being funded, one of which is the first of its kind in the Western Hemisphere. Among other capabilities, these instruments help researchers in drug discovery and biotherapeutics research.
  • Announced Oct. 2019

Light Sheet Microscope

  • Biomedical Research Core Facilities Microscopy Core
  • Principal investigator Aaron Taylor, managing director of the Microscopy and Image Analysis Laboratory
  • Uses a very thin sheet of light, allowing users to examine living cells and embryos in 3-D.
  • Announced Oct. 2019

Acoustic Liquid Handler

  • Center for Chemical Genomics
  • Principal investigator Andrew Alt, director of the Center for Chemical Genomics
  • Emits sound waves to dispense incredibly small samples, furthering drug discovery and efficient screening of drug libraries.
  • Announced Oct. 2019

Nuclear Magnetic Resonance Instrumentation

  • BioNMR Core
  • Principal investigator Emily Scott, professor of medicinal chemistry, of pharmacology, and of biophysics
  • Analyzes molecules to expand the development of anti-cancer therapeutics and drug metabolism studies.
  • Announced Oct. 2019